Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 64 HER2-positive Breast Cancer 11 Carcinoma, Non-Small-Cell Lung 6 HER2 Positive Metastatic Breast Cancer 4 Breast Diseases 4 Brain Neoplasms 4 HER2 Positive Breast Cancer 3 Advanced Breast Cancer 3 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 HER2-positive Metastatic Breast Cancer 2 Colorectal Neoplasms 2 Breast Cancer Invasive 2 Breast Cancer Female 2 Solid Tumor 1 Salivary Gland Neoplasms 1 Rare Tumour 1 Rare Tumor 1 Pathologic Complete Response 1 Non-squamous NSCLC 1 Non Small Cell Lung 1 Neoplasm Metastasis 1 Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1 Metastatic Breast Cancer in the Brain 1 Lung Neoplasms 1 Locally Advanced Breast Cancer 1 HER2-positive Early Breast Cancer 1 HER2-expressing Advanced Solid Tumors 1 HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane 1 HER2+ Early or Locally Advanced Breast Cancer 1

Interventions

pyrotinib 1 Platinum 1 Injections 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Non-squamous NSCLC × pyrotinib × Clear all

NCT04447118 2025-12-19

PYRAMID-1

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed

Non-squamous NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡